GH Research (GHRS) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.28B and a free-cash-flow yield of -3.9%. Nama's AI scorecard rates it Sell, 4.0 out of 10. On 12-month momentum it ranks in the rising band of its market.
AI scorecard
Sell · 4.0/10
Negative, at the mild end of Sell. As of Nov 7, 2026.
Momentum
Rising · +57.0% over 12 months ex. last
Second-best fifth of its market on the past year's move.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-40.8%
How far the last close sits under the highest price of the past five years.
Market cap
$1.28B
Trailing P/E
—
Price / book
3.5
Price / sales
—
FCF yield
-3.9%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
1.3
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
GHRS earnings
Next report: Nov 9, 2026 (Q3 2026, EPS estimate -$0.30).
Beat the EPS estimate in 2 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q2 2026
Aug 6, 2026
-$0.23
-$0.33
+30.3%
$0
Q1 2026
May 14, 2026
-$0.31
-$0.26
-19.2%
$0
Q4 2025
Mar 5, 2026
-$0.22
-$0.27
+18.5%
$0
Q3 2025
Nov 6, 2025
-$0.23
-$0.23
+0.0%
$0
GHRS analyst price target
Median target $40.00 from 9 analysts, ranging $38.00 – $65.00.
Nama's AI scorecard currently rates GH Research Sell (4.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does GHRS report earnings?
GH Research's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$0.30.
What is the GHRS price target?
The median analyst price target from 9 analysts is $40.00, with a range of $38.00 – $65.00.
Is GHRS Shariah compliant?
Nama's AAOIFI-style screen reads GH Research as Not Shariah Compliant. At least one of the three ratios or the industry test failed.